Finding a way to combat long COVID
A new has identified potential neurological biomarkers of long COVID-19 in nonhuman primates that may help physicians diagnose, monitor and treat this condition.
Over worldwide have developed long COVID after being infected with SARS-CoV-2, and cases are only becoming more common. symptoms can last weeks, months or years. Even more perplexing is the fact that symptoms can vary widely between individuals and consist of any combination of fatigue, fever, chest pain, trouble breathing, neurological symptoms such as “brain fog,” and many more. Long COVID puts a gigantic burden on the , and some doctors doubt the condition exists, leaving some patients unable to find care.
A team of researchers at Tulane University is trying to shed light on this condition and find tools to manage it. They published their work in the journal 麻豆传媒色情片 & Cellular Proteomics.

“Our primary goal was to better understand the inside of the brain after COVID infection,” said Jia Fan, an assistant professor of biochemistry and molecular biology who oversaw the study. “This understanding could provide a potential target to use in the clinic for long COVID evaluation and monitoring. We also thought this study may give us some clues to find a potential treatment strategy for long COVID in patients.”
However, because long COVID can vary drastically between individuals, studying this disorder has been difficult for scientists and clinicians alike.
“There's a very limited understanding of the neuropathogenesis of long COVID,” Fan said. “It is almost impossible to get any brain tissue or samples of any kind from patients that have mild symptoms or no long COVID symptoms because there is no reason for invasive procedures.”
Therefore, the group turned to a nonhuman primate model of long COVID. They used two different types of nonhuman primates, the rhesus macaque and the African green monkey, to mimic the genetic differences seen in humans.

“Macaques are bred in captivity,” Sudipa Maity, a postdoctoral fellow at Tulane and lead author of the study, said. “So, they are born, fed and live their entire life in the research center. They also have very similar genetic backgrounds. On the contrary, the African green monkeys live in the wild and are brought to the center around one year before the study. Therefore, the individual genetic variations are larger in the African green monkey than the rhesus macaque.”
The team found that certain proteins associated with neurodegenerative disorders, such as Parkinson's disease, were elevated in the brain, cerebrospinal fluid and blood after SARS-CoV-2 infection even in nonhuman primates that showed mild or no symptoms. Maity explained that these elevated proteins indicate that the immune systems of the monkeys remained activated even after infection.
“Our findings suggest that the major neurological complications are arising due to the body's natural immune defenses,” Maity said. “The immune system has a very important and significant impact on the neurological complications of COVID.”
The next steps of the project involve validating the biomarkers the team identified in human samples such as blood, said Fan.
“It is currently hard to score the severity of (long COVID) patient symptoms because they are based on self-reports,” Fan said. “If we can find a group of proteins in the blood associated with long COVID, this is a less invasive way to easily evaluate the severity of the long COVID patients. We hope what we started can provide a clue to find a potential treatment to better the long COVID patient experience.”

Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto鈥揜yu鈥揗alicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer鈥檚 spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting 鈥渦ndruggable鈥 molecules.

How HCMV hijacks host cells 鈥 and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.